A Phase 1/2 interventional study of Linvoseltamab and REGN7945+Linvoseltamab in Relapsed/Refractory Multiple Myeloma, sponsored by Regeneron Pharmaceuticals. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.
Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 8th largest by planned enrollment, is one of 4 that started in 2024, is one of 5 in phase 1/2, reaches primary completion later than 11 of the 14 other live ones, and was the 7th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, France, Japan and 3 more countries
Ages 18+
Multiple Myeloma Research Consortium · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 5 · Phase 4 1
First in 2019; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 186 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 168 across the 16 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
15 studies in Multiple Myeloma by Regeneron Pharmaceuticals: 9 open now, 11 under way, 3 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 15 studies in Multiple Myeloma by Regeneron Pharmaceuticals, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 1/2, reaches primary completion later than 9 of the 10 other live ones, and was the 10th registered.
Regeneron Pharmaceuticals’s Multiple Myeloma studies by the year they started, since 2019.
2 of the studies testing linvoseltamab in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376526Dickran Kazandjian, MDIMMUNOPLANT for Newly Diagnosed Multiple Myeloma | 2027-08-31 |
| NCT07609940Regeneron PharmaceuticalsAdult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | 2027-10-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing linvoseltamab in Multiple Myeloma, from their registry updates:
Among Regeneron Pharmaceuticals’s 15 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined).
This study is the first time REGN7945 will be tested in humans. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after several other therapies had failed.
The aim of the study is to see how safe, tolerable, and effective REGN7945 is when given in combination with linvoseltamab, compared with linvoseltamab alone.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1 Phase 2
Drug: REGN7945+Linvoseltamab
Phase 2
Drug: Linvoseltamab · Drug: REGN7945+Linvoseltamab
Administered per protocol
Also known as: REGN5458
Drug page: Linvoseltamab
Administered per protocol
Incidence of dose limiting toxicities (DLTs) from the first dose of REGN7945 in combination with linvoseltamab
Phase 1
Time frame: Up to 21 days
Incidence of treatment emergent adverse events (TEAEs) during the treatment period with REGN7945 in combination with linvoseltamab
Phase 1
Time frame: Up to 5 years
Severity of TEAEs during the treatment period with REGN7945 in combination with linvoseltamab
Phase 1
Time frame: Up to 5 years
Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination therapy
Phase 2
Time frame: Within 12 weeks of starting cycle 1
VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapy
Phase 2
Time frame: Within 12 weeks of starting cycle 1
Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination therapy
Phase 2
Time frame: Within 12 weeks of starting cycle 1
PR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapy
Phase 2
Time frame: Within 12 weeks of starting cycle 1
Incidence of TEAEs
Phase 1 and Phase 2
Time frame: Up to 5 years
Severity of TEAEs
Phase 1 and Phase 2
Time frame: Up to 5 years
Concentrations of REGN7945 in the serum
Phase 1 and Phase 2
Time frame: Up to 5 years
Concentrations of linvoseltamab in the serum
Phase 1 and Phase 2
Time frame: Up to 5 years
Incidence of anti-drug antibodies (ADA) to REGN7945
Phase 1 and Phase 2
Time frame: Up to 5 years
Titer of ADA to REGN7945
Phase 1 and Phase 2
Time frame: Up to 5 years
Incidence of ADA to linvoseltamab
Phase 1 and Phase 2
Time frame: Up to 5 years
Titer of ADA to linvoseltamab
Phase 1 and Phase 2
Time frame: Up to 5 years
Change in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) Global Health Status / Quality of Life (GHS/QoL)
Phase 1 and Phase 2 The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported quality of life using one global health status/quality of life (GHS/QoL) scale, 5 functioning scales (physical, role, emotional, cognitive, and social) ranging from from 1 = "very poor" to 5 = "excellent" and 9 symptom scales/items (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) among patients with cancer, ranging from 1 = "not at all" to 9 = "very much" higher scores indicate higher symptom burden.
Time frame: Up to 5 years
Change in EORTC QLQ-C30 Physical Functioning (PF)
Phase 1 and Phase 2
Time frame: Up to 5 years
Change in EORTC QLQ-C30 Role Functioning (RF)
Phase 1 and Phase 2
Time frame: Up to 5 years
Change in EORTC QLQ-C30 pain
Phase 1 and Phase 2
Time frame: Up to 5 years
Change in EORTC QLQ-C30 fatigue
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 GHS/QoL
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 PF
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 RF
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 pain
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-C30 fatigue
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 GHS/QoL
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 PF
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 RF
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 pain
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-C30 fatigue
Phase 1 and Phase 2
Time frame: Up to 5 years
Change in EORTC QLQ-Multiple Myeloma Module (MY20) Disease Symptoms (DS)
Phase 1 and Phase 2 The EORTC QLQ-MY20 is a self -administered instrument to assess QoL in persons with Multiple Myeloma (MM). This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item). A high score represents a high level of symptoms or problems.
Time frame: Up to 5 years
Change in EORTC QLQ-MY20 Treatment Side Effects (TSE)
Phase 1 and Phase 2
Time frame: Up to 5 years
Change in EORTC QLQ-MY20 Body Image (BI)
Phase 1 and Phase 2
Time frame: UP to 5 years
Change in EORTC QLQ-MY20 Future Perspective (FP)
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-MY20 DS
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-MY20 TSE
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-MY20 BI
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to definitive deterioration in EORTC QLQ-MY20 FP
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-MY20 DS
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-MY20 TSE
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-MY20 BI
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EORTC QLQ-MY20 FP
Phase 1 and Phase 2
Time frame: Up to 5 years
Change in EuroQoL-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS) (EQ-5D-5L VAS)
Phase 1 and Phase 2 The EQ-5D-5L is a generic questionnaire that measures Health-Related Quality of Life (HRQoL) across 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) across 5 levels (no problems, slight problems, some problems, severe problems and extreme problems) and a visual analogue scale (VAS).
Time frame: Up to 5 years
Time to definitive deterioration in EQ-5D-5L VAS
Phase 1 and Phase 2
Time frame: Up to 5 years
Time to first improvement in EQ-5D-5L VAS
Phase 1 and Phase 2
Time frame: Up to 5 days
Patient-reported overall impact of treatment toxicity measured by Functional Assessment of Cancer Therapy (FACIT)-Item GP5
Phase 1 and Phase 2 FACIT-Item GP5 will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much).
Time frame: Up to 5 years
Objective Response Rate (ORR) as measured by IMWG criteria as determined by the investigator
Phase 1
Time frame: Up to 5 years
Complete response (CR) rate as measured by IMWG criteria as determined by the investigator
Phase 1
Time frame: Up to 5 years
Duration of response (DOR) by IMWG criteria as determined by the investigator
Phase 1
Time frame: Up to 5 years
Progression Free Survival (PFS) as measured by IMWG criteria as determined by the investigator
Phase 1
Time frame: Up to 5 years
Achievement of Minimal Residual Disease (MRD) negative status (at 10^5) in participants in CR or better
Phase 1
Time frame: Up to 5 years
Overall survival (OS)
Phase 1
Time frame: Up to 5 years
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Nov 2033, 107 months after the start.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 107 months is above that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linvoseltamab